Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Major Depressive Disorder Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

24 recruiting trials for Major Depressive Disorder. Eligibility criteria explained in plain English.

TrialFinderData lists 24 Major Depressive Disorder clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 2 is the largest group at 40% (4 studies); the largest phase groups are Phase 2: 4, Phase 4: 2, Phase 3: 2, Phase 1 / Phase 2: 1.

Research is led by Massachusetts General Hospital (2), Rotman Research Institute at Baycrest (1), King's College London (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Placebo (drug, 4 trials), followed by Ketamine, Sertraline.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
24
Total Trials
24
Recruiting Now
2
Phase 3 Trials
10
Sponsors

Track Major Depressive Disorder trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT03665831

Deep TMS for Comorbid Depression and Cognitive Impairment in Older Adults

In this study, the investigators will be examining the effects of the deep repetitive transcranial magnetic stimulation (rTMS) using the H1 coil in patients over the age of 60...

Sponsor: Rotman Research Institute at BaycrestEnrolling: 281 location
RECRUITINGPhase 2NCT06309472

Trial of Mirtazapine for Depression in IBD

This study will test whether it is feasible to conduct a clinical trial of mirtazapine (an antidepressant tablet) in patients who have both depression and inflammatory bowel...

Sponsor: King's College LondonEnrolling: 764 locations
RECRUITINGPhase 4NCT06610305

Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression

The goal of this clinical trial is to learn how hormonal changes over the menstrual cycle affect mood symptoms in reproductive-aged women with depression that worsens during the...

Sponsor: University of North Carolina, Chapel HillEnrolling: 751 location
RECRUITINGPhase 2NCT05570812

Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV

This study will determine the effects of pregnenolone on brain function, inflammation and depressive symptoms in people with HIV who have depression. Participants in this study...

Sponsor: Massachusetts General HospitalEnrolling: 1201 location
RECRUITINGPhase 3NCT06911112

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants...

The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

Sponsor: Neurocrine BiosciencesEnrolling: 20010 locations
RECRUITINGNCT05366270

Peripheral Neuroimmune Mechanisms of Hyperthermia

The goal of this study is to examine how whole-body hyperthermia affects the thermoinflammatory profile, which includes the combined immune and heat shock response, in patients...

Sponsor: Massachusetts General HospitalEnrolling: 601 location
RECRUITINGNCT06976840

Rapid Antidepressant Dynamics in Acute Neuromodulation Treatments

The goal of this clinical trial is to learn how different types of non-invasive brain stimulation affect mood and brain function in adults with major depressive disorder (MDD). It...

Sponsor: Marta Peciña, MD PhDEnrolling: 2001 location
RECRUITINGNCT04480918

University of Iowa Interventional Psychiatry Service Patient Registry

The purpose of this study is to examine the effects of interventional/procedural therapies for treatment-resistant depression (TRD) and Obsessive-Compulsive Disorder (OCD). These...

Sponsor: Mark NiciuEnrolling: 10001 location
RECRUITINGNCT07242105

Optimizing Brain Excitability in Depression

The goal of this study is to improve depression treatment by establishing reliable prefrontal excitability markers through Targeting with Automated Real-time Guidance for...

Sponsor: Stanford UniversityEnrolling: 1452 locations
RECRUITINGNCT05437588

Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in...

This study is dedicated to help identify biomarkers for depression and suicide. The purpose of the study is to better understand these links to improve medical and psychiatric...

Sponsor: University of Alabama at BirminghamEnrolling: 2402 locations
RECRUITINGPhase 2NCT04637620

NMDA Modulation in Major Depressive Disorder

Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA...

Sponsor: China Medical University HospitalEnrolling: 901 location
RECRUITINGNCT06080646

Reward Processing and Depressive Subtypes: Identifying Neural Biotypes

Deficits in motivation and pleasure are common in depression, and thought to be caused by alterations in the ways in which the brain anticipates, evaluates, and adaptively uses...

Sponsor: San Francisco Veterans Affairs Medical CenterEnrolling: 1501 location
RECRUITINGPhase 2NCT05786066

The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects

The purpose of this study is to test the hypothesis that the anti-depressant and anti-suicidal effects of the N-methyl-D-aspartate receptor (NMDAR) antagonist Ketamine is...

Sponsor: Yale UniversityEnrolling: 301 location
RECRUITINGNCT06070766

RIVER At Home Ketamine Protocols

Multiple site studies with the recruitment of other sub-investigators and sites. It's sobering to consider how chronic illness makes us more vulnerable to suicidal thoughts and...

Sponsor: RIVER FoundationEnrolling: 500002 locations
RECRUITINGPhase 3NCT05603104

Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a...

Schizophrenia, bipolar and major depressive disorders collectively affect over 10 million people across the EU and are associated with annual healthcare and societal costs in...

Sponsor: Dr. Inge WinterEnrolling: 12541 location
RECRUITINGPhase 4NCT06417437

Non-invasive BCI and Application Verification for Depressed People

Major Depressive Disorder (MDD) is a serious mental illness and public health problem that poses threat to both physical and mental health. According to statistics from WHO, it is...

Sponsor: Shanghai Mental Health CenterEnrolling: 4001 location
RECRUITINGPhase 1 / Phase 2NCT07185815

Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine...

The purpose of this study is to assess the PK, Safety, Tolerability (all cohorts) and Efficacy (cohort 3), of once-a-month long-acting SC injection of dose escalating Cariprazine...

Sponsor: Mapi Pharma Ltd.Enrolling: 246 locations
RECRUITINGNCT06897670

Identifying Cerebral Hemodynamic Patterns in Mood Disorders and Mild Cognitive Impairment: A Functional Near-Infrared...

The purpose of this research is to measure brain activity in individuals with mood disorders and memory problems using a simple, safe, and noninvasive method called functional...

Sponsor: Mayo ClinicEnrolling: 2001 location
RECRUITINGPhase 2 / Phase 3NCT06529029

Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy

This protocol proposes an initial randomized clinical trial that includes all patients with suicidal ideation (SI) at baseline, and with SI as the primary outcome measure to...

Sponsor: Michigan State UniversityEnrolling: 301 location
RECRUITINGNCT06462196

Natural History of Depression, Bipolar Disorder and Suicide Risk

Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and...

Sponsor: National Institute of Mental Health (NIMH)Enrolling: 5001 location
RECRUITINGNCT07316803

Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness

This study evaluates a group-based intervention designed to improve romantic and social relationship skills in adults living with a severe mental illness (SMI), such as...

Sponsor: Centre hospitalier de Ville-Evrard, FranceEnrolling: 202 locations
RECRUITINGNCT06507787

Evaluation of the Impact of the EDIT-B® Blood Test on the Health Status of Patients Presenting a Major Depressive...

Depression is one of the most common mental disorders, affecting nearly 10% of men and 20% of women worldwide. It is associated with a significant increase in mortality, mainly...

Sponsor: AlcediagEnrolling: 4507 locations
RECRUITINGNCT06763081

Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation

The purpose of this study is to identify and validate a panel of genetic markers associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioural activation in...

Sponsor: University of ManitobaEnrolling: 1602 locations
RECRUITINGNCT03953014

Pharmacogenetics of Antidepressant-Induced Disinhibition

The purpose of this study is to identify pharmacogenetic profiles associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioral disinhibition in children with...

Sponsor: University of CalgaryEnrolling: 1201 location

Frequently Asked Questions

There are currently 24 clinical trials for Major Depressive Disorder, with 24 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Major Depressive Disorder, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 2 Phase 3 trials for Major Depressive Disorder, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.